Please login to the form below

Not currently logged in
Email:
Password:

Janssen’s Leisha Daly appointed VP of IPHA

Joins Irish trade body for pharma as plan to cut country’s drug prices agreed

Leisha Daly, IPHAThe Irish Pharmaceutical Healthcare Association (IPHA) has appointed Janssen's Dr Leisha Daly as vice president.

Dr Daly, who serves as country director at Janssen, joins the trade body at a crucial time for the pharma industry in Ireland, with the IPHA this week agreeing plans with the Department of Health and Health Service Executive (HSE) to cut the price of hundreds of medicines by an average of 10 per cent.

She takes over from Pfizer's David Gallagher as vice president, following his two years in the position, and will serve alongside fellow vice president Dr Neil Boyle of MSD.

In addition to her role at Janssen, Dr Daly has served on the IPHA board of directors since June, 2012, and was appointed to the prescription medicines division strategy board in August, 2012.

Dr Daly joined Janssen in 1998 as head of technical affairs, rising up the ranks to hold a variety of senior positions in medical, sales and marketing, before being appointed to her current position in March, 2012.

Prior to joining Janssen, Dr Daly served at Hoechst Ireland having spent several years in academic clinical research.

25th October 2012

From: Research, Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics